These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 7622906)

  • 1. Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus pneumoniae infection in mice.
    Alonso De Velasco E; Dekker BA; Verheul AF; Feldman RG; Verhoef J; Snippe H
    J Infect Dis; 1995 Aug; 172(2):562-5. PubMed ID: 7622906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines.
    DeVelasco EA; Dekker HA; Antal P; Jalink KP; van Strijp JA; Verheul AF; Verhoef J; Snippe H
    Vaccine; 1994 Nov; 12(15):1419-22. PubMed ID: 7887020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Th1-directing adjuvants increase the immunogenicity of oligosaccharide-protein conjugate vaccines related to Streptococcus pneumoniae type 3.
    Lefeber DJ; Benaissa-Trouw B; Vliegenthart JF; Kamerling JP; Jansen WT; Kraaijeveld K; Snippe H
    Infect Immun; 2003 Dec; 71(12):6915-20. PubMed ID: 14638780
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isotypes and opsonophagocytosis of pneumococcus type 6B antibodies elicited in infants and adults by an experimental pneumococcus type 6B-tetanus toxoid vaccine.
    Vidarsson G; Sigurdardottir ST; Gudnason T; Kjartansson S; Kristinsson KG; Ingolfsdottir G; Jonsson S; Valdimarsson H; Schiffman G; Schneerson R; Jonsdottir I
    Infect Immun; 1998 Jun; 66(6):2866-70. PubMed ID: 9596761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction of Streptococcus pneumoniae Colonization and Dissemination by a Nonopsonic Capsular Polysaccharide Antibody.
    Doyle CR; Pirofski LA
    mBio; 2016 Feb; 7(1):e02260-15. PubMed ID: 26838726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1.
    McLay J; Leonard E; Petersen S; Shapiro D; Greenspan NS; Schreiber JR
    J Immunol; 2002 Apr; 168(7):3437-43. PubMed ID: 11907102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of antibody responses to pneumococcal vaccines with ELISA and opsonophagocytic assay.
    Kim KH; Seoh JY
    J Korean Med Sci; 1999 Oct; 14(5):475-9. PubMed ID: 10576141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgG subclass response and opsonization of Streptococcus pneumoniae after vaccination of healthy adults.
    Bardardottir E; Jonsson S; Jonsdottir I; Sigfusson A; Valdimarsson H
    J Infect Dis; 1990 Aug; 162(2):482-8. PubMed ID: 2373875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Opsonization and antibodies to capsular and cell wall polysaccharides of Streptococcus pneumoniae.
    Vitharsson G; Jónsdóttir I; Jónsson S; Valdimarsson H
    J Infect Dis; 1994 Sep; 170(3):592-9. PubMed ID: 8077716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct approaches to investigate the importance of the murine 4-1BB 4-1BBL interaction in the antibody response to Streptococcus pneumoniae.
    Moens L; Jeurissen A; Mittler RS; Wuyts G; Michiels G; Boon L; Ceuppens JL; Bossuyt X
    J Leukoc Biol; 2007 Sep; 82(3):638-44. PubMed ID: 17550973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy of pneumococcal capsular polysaccharide-specific antibodies to serotype 3 Streptococcus pneumoniae requires macrophages.
    Fabrizio K; Manix C; Tian H; van Rooijen N; Pirofski LA
    Vaccine; 2010 Nov; 28(47):7542-50. PubMed ID: 20800700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enzyme immunoassay for detection of immunoglobulin G (IgG), IgM, and IgA antibodies against type 6B pneumococcal capsular polysaccharide and cell wall C polysaccharide in chinchilla serum.
    Koskela M; Harris M; Giebink GS
    J Clin Microbiol; 1992 Jun; 30(6):1485-90. PubMed ID: 1624568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional anti-polysaccharide IgG titres induced by unadjuvanted pneumococcal-conjugate vaccine when delivered by microprojection-based skin patch.
    Pearson FE; Muller DA; Roalfe L; Zancolli M; Goldblatt D; Kendall MA
    Vaccine; 2015 Nov; 33(48):6675-83. PubMed ID: 26518398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum antibody and opsonic responses to vaccination with pneumococcal capsular polysaccharide in normal and splenectomized children.
    Giebink GS; Foker JE; Kim Y; Schiffman G
    J Infect Dis; 1980 Mar; 141(3):404-12. PubMed ID: 6988526
    [No Abstract]   [Full Text] [Related]  

  • 15. Compound 48/80 acts as a potent mucosal adjuvant for vaccination against Streptococcus pneumoniae infection in young mice.
    Zeng L; Liu Y; Wang H; Liao P; Song Z; Gao S; Wu Y; Zhang X; Yin Y; Xu W
    Vaccine; 2015 Feb; 33(8):1008-16. PubMed ID: 25595867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Decreased serum opsonic activity against Streptococcus pneumoniae in human immunodeficiency virus-infected Ugandan adults.
    Takahashi H; Oishi K; Yoshimine H; Kumatori A; Moji K; Watanabe K; Nalwoga H; Tugume SB; Kebba A; Mugerwa R; Mugyenyi P; Nagatake T
    Clin Infect Dis; 2003 Dec; 37(11):1534-40. PubMed ID: 14614677
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production, binding characteristics and protective immunity of monoclonal antibody to pneumococcal type-9V conjugate.
    Lee CJ; Karpas A; Wang TR; Kosaka T; Koizumi K
    Microbiol Immunol; 1996; 40(11):857-65. PubMed ID: 8985941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a conjugate vaccine against invasive pneumococcal disease based on capsular polysaccharides coupled with PspA/family 1 protein of Streptococcus pneumoniae.
    Lin H; Peng Y; Lin Z; Zhang S; Guo Y
    Microb Pathog; 2015; 83-84():35-40. PubMed ID: 25959527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines.
    de Velasco EA; Merkus D; Anderton S; Verheul AF; Lizzio EF; Van der Zee R; Van Eden W; Hoffman T; Verhoef J; Snippe H
    Infect Immun; 1995 Mar; 63(3):961-8. PubMed ID: 7532630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.